---
title: "Junshi Biosciences Completes RMB300 Million Technology Innovation Bond Issuance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293479960.md"
description: "Shanghai Junshi Biosciences completed the issuance of its 2026 second tranche of technology innovation bonds, raising RMB300 million. The three-year bond carries a 2.59% coupon and matures on July 22, 2029. Funds received on July 22, 2026, will reinforce the company's capital structure to support innovation-linked activities in China. This issuance is part of a registered medium-term note program."
datetime: "2026-07-22T13:08:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293479960.md)
  - [en](https://longbridge.com/en/news/293479960.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293479960.md)
generator: "portal-rs"
---

# Junshi Biosciences Completes RMB300 Million Technology Innovation Bond Issuance

An update from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.

Shanghai Junshi Biosciences has completed the issuance of its 2026 second tranche of technology innovation bonds, raising RMB0.3 billion with a three-year term and a 2.59% coupon, maturing on July 22, 2029. The funds were received on July 22, 2026, reinforcing the company’s capital structure to support ongoing innovation-linked activities in China’s financial markets.

The bonds were issued under a previously registered medium-term note program with the National Association of Financial Market Institutional Investors, and related documentation has been published on recognized Chinese financial platforms. The company has advised shareholders and potential investors to exercise caution when trading its securities, underscoring standard market risk awareness around new debt issuance and its implications for overall leverage and future financial performance.

The most recent analyst rating on (HK:1877) stock is a Hold  
 with a HK$34.70 price target.  
 To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock,  
 see the HK:1877 Stock Forecast page. 

**More about Shanghai Junshi Biosciences Co., Ltd. Class H**

Shanghai Junshi Biosciences Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong, focusing on the research, development and commercialization of innovative medicines. The firm operates in the biotechnology and pharmaceutical sector, targeting technology-driven innovation to support its growth and funding needs in domestic and international capital markets.

The company is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a corporate structure aimed at balancing scientific leadership with capital market oversight. Its use of technology innovation bonds indicates an emphasis on financing R&D-intensive operations while maintaining access to China’s institutional investor base.

**Average Trading Volume:** 4,022,485

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$36.73B

Learn more about 1877 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [01877.HK](https://longbridge.com/en/quote/01877.HK.md)
- [688180.CN](https://longbridge.com/en/quote/688180.CN.md)

## Related News & Research

- [Junshi Biosciences Shareholders Approve H-Share Buyback Mandate](https://longbridge.com/en/news/293923779.md)
- [Shanghai Junshi Biosciences Calls 2025 AGM and Seeks Mandate for RMB 2.5 Billion Debt Issuance](https://longbridge.com/en/news/288928914.md)
- [Zhejiang Galaxis Sets Board Meeting to Approve 2026 Interim Results](https://longbridge.com/en/news/296183592.md)
- [Hong Kong Exchange renews CEO Chan’s contract as IPOs boom](https://longbridge.com/en/news/296192704.md)
- [Banco Santander-Chile Issues USD 15 Million EMTN Bond Disclosed as Material Fact](https://longbridge.com/en/news/296520121.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**